Success Metrics

Completion Rate
0%(0/1)
Active Trials
5(63%)
Terminated
1(13%)

Phase Distribution

Ph phase_3
2
25%
Ph phase_1
1
13%
Ph phase_2
4
50%

Phase Distribution

1

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
2(28.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

8

all time

Status Distribution
Active(5)
Terminated(2)
Other(1)

Detailed Status

Recruiting3
Active, not recruiting2
Terminated1
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
5
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 24 (57.1%)
Phase 32 (28.6%)

Trials by Status

active_not_recruiting225%
recruiting338%
terminated113%
withdrawn113%
unknown113%

Recent Activity

5 active trials
Showing 5 of 8
recruitingphase_2

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

NCT07323641
recruitingphase_3

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT04928846
recruitingphase_2

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06568939
unknown

Expanded Access to Telisotuzumab Vedotin

NCT04830202
active_not_recruitingphase_2

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

NCT03539536
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07323641Phase 2

Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer

Recruiting
NCT04928846Phase 3

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT06568939Phase 2

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
NCT04830202

Expanded Access to Telisotuzumab Vedotin

Unknown
NCT03539536Phase 2

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

Active Not Recruiting
NCT05513703Phase 2

A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Terminated
NCT02099058Phase 1

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Active Not Recruiting
NCT06093503Phase 3

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8